Composition for improving bone joint health and preparation method and application thereof

Abstract

The invention provides a composition for improving bone joint health as well as a preparation method and application thereof, and relates to the technical field of bone joint health products. The composition for improving bone joint health is prepared from the following components in parts by mass: 0.5 to 5 parts of collagen peptide, 5 to 30 parts of mangosteen extract, 0.5 to 3 parts of non-denatured II type collagen peptide, 0.1 to 2 parts of milk mineral salt, 0.3 to 3 parts of bone collagen peptide, 0.1 to 2 parts of cartilage extract, 0.1 to 2 parts of N-acetylglucosamine, 0.1 to 2 parts of sodium hyaluronate and 0.3 to 3 parts of turmeric extract. The composition obtained by repeatedly compounding the mangosteen extract, the turmeric extract, the cartilage extract and the sodium hyaluronate has the advantages of low cost and high safety, and has a better effect on preventing or improving osteoarthrosis.

Description

Technical Field

[0001] The present invention belongs to the technical field of bone and joint health products, and specifically relates to a composition for improving bone and joint health, and a preparation method and application thereof. Background Art

[0002] Osteoarthritis, also known as degenerative osteoarthritis or osteoarthritis, is a disease caused by the destruction of articular cartilage, resulting in bone pain, stiffness and limited mobility. It is a common disease in clinical practice, especially in the middle-aged and elderly population. It often occurs in the knee joints, spine, hip joints and interphalangeal joints that bear heavy loads. The traditional treatment for osteoarthritis is to take anti-inflammatory analgesics after the onset of the disease. Commonly used drugs include acetaminophen, nonsteroidal anti-inflammatory drugs (anti-inflammatory drugs for short), and opioids. Although the above drugs can relieve the symptoms of pain to a certain extent, they only treat the symptoms and not the root cause, and have strong side effects. Long-term use can cause damage to the liver, kidneys and digestive tract.

[0003] Chinese invention patent application CN109106944A discloses a composition for preventing and treating osteoarthritis and its application, the composition contains non-denatured type II collagen and cartilage collagen peptide, and the weight ratio of the non-denatured type II collagen and the cartilage collagen peptide is most preferably 1:1.5-6, and the composition also contains one or more of licorice extract, houttuynia extract, turmeric and vitamin C. However, due to the high price of non-denatured type II collagen and cartilage collagen peptide, the product composed of non-denatured type II collagen and cartilage collagen peptide as the main raw materials is expensive, and its effect needs to be further improved.

[0004] Chinese invention patent CN116726141 B discloses a composition for preventing and relieving osteoarthritis and its application. The composition for preventing and relieving osteoarthritis is made of the following raw materials in parts by weight: 0.5-2 parts of vitamin C, 25-37 parts of glucosamine derivatives, 0.3-0.6 parts of manganese gluconate, 15-30 parts of dimethyl sulfone, 1-1.2 parts of boron-containing compounds, 4.4-10 parts of chondroitin sulfate, 4-8 parts of lemon flavonoids, 4.4-8 parts of collagen peptide powder, 0.5-5 parts of serrata extract, 1-3 parts of turmeric extract, and 0.04-0.15 parts of sodium hyaluronate. The present invention has a good effect on the prevention and treatment of osteoarthritis and has no side effects. However, the dimethyl sulfone contained in the raw materials has carcinogenic, teratogenic, sensitizing, irritating and other hazards. Long-term use may cause an imbalance of trace elements in the body, endocrine disorders, and liver and kidney damage. Therefore, its safety needs to be further improved.

[0005] Therefore, there is an urgent need to develop a composition with low cost, high safety and good prevention or improvement effect on osteoarthritis. Summary of the invention

[0006] The present invention aims at the problems existing in the prior art and provides a composition for improving bone and joint health, a preparation method and an application thereof. The present invention adopts multiple compounding of mangosteen extract, turmeric extract, cartilage extract and sodium hyaluronate to obtain a composition with low cost, high safety and good prevention or improvement effect on bone and joint diseases.

[0007] One of the purposes of the present invention is to provide a composition for improving bone and joint health. The composition comprises the following components by mass: 0.5-5 parts of collagen peptide, 5-30 parts of mangosteen extract, 0.5-3 parts of non-denatured type II collagen peptide, 0.1-2 parts of milk mineral salt, 0.3-3 parts of bone collagen peptide, 0.1-2 parts of cartilage extract, 0.1-2 parts of N-acetylglucosamine, 0.1-2 parts of sodium hyaluronate, and 0.3-3 parts of turmeric extract.

[0008] Preferably, the composition comprises the following components in parts by mass: 0.8-3 parts of collagen peptide, 5-20 parts of mangosteen extract, 1-2.5 parts of non-denatured type II collagen peptide, 0.1-1.2 parts of milk mineral salt, 0.5-2 parts of bone collagen peptide, 0.1-1 parts of cartilage extract, 0.1-1 parts of N-acetylglucosamine, 0.1-1 parts of sodium hyaluronate, and 0.5-2 parts of turmeric extract.

[0009] Preferably, the composition comprises the following components by mass: 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 0.8 parts of turmeric extract.

[0010] Preferably, the weight ratio of the mangosteen extract to the cartilage extract is 60-80:1.

[0011] Preferably, the weight ratio of the cartilage extract, sodium hyaluronate and turmeric extract is 1-3:1-3:6-10.

[0012] Preferably, the composition further comprises food grade auxiliary materials.

[0013] Preferably, the auxiliary material is selected from at least one of hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sorbitol, citric acid, xanthan gum, sucralose, maltodextrin, soluble starch and lactose.

[0014] Further preferably, the excipients are hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose and sorbitol.

[0015] The second aspect of the present invention is to provide a method for preparing the above-mentioned composition, comprising the following steps:

[0016] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate, turmeric extract and food-grade auxiliary materials.

[0017] The third aspect of the present invention is to provide the use of the above composition or the composition prepared according to the above preparation method in the preparation of products for preventing or improving osteoarthritis.

[0018] Preferably, the product is in the form of a liquid dosage form, a jelly dosage form, a gel candy, a compressed candy or a powder.

[0019] Compared with the prior art, the present invention has the following beneficial effects: the composition obtained by the present invention through the multiple compounding of mangosteen extract and turmeric extract, cartilage extract and sodium hyaluronate has the characteristics of low cost and high safety, and has a good preventive or improving effect on osteoarthritis. The effect of the composition of the present invention is significantly better than that of each comparative example and the blank control group. DETAILED DESCRIPTION

[0020] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0021] It is worth noting that the raw materials used in the present invention are all common commercially available products, and their sources are not specifically limited.

[0022] Embodiment 1:

[0023] 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 0.8 parts of turmeric extract.

[0024] Preparation method:

[0025] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0026] Embodiment 2:

[0027] A composition for improving bone and joint health, comprising the following components by mass: 0.8 parts of collagen peptide, 5 parts of mangosteen extract, 1 part of non-denatured type II collagen peptide, 0.1 parts of milk mineral salt, 0.5 parts of bone collagen peptide, 0.1 parts of cartilage extract, 0.1 parts of N-acetylglucosamine, 0.1 parts of sodium hyaluronate, and 0.5 parts of turmeric extract.

[0028] Preparation method:

[0029] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0030] Embodiment 3:

[0031] A composition for improving bone and joint health, comprising the following components by mass: 3 parts of collagen peptides, 20 parts of mangosteen extract, 2.5 parts of non-denatured type II collagen peptides, 1.2 parts of milk mineral salts, 2 parts of bone collagen peptides, 1 part of cartilage extract, 1 part of N-acetylglucosamine, 1 part of sodium hyaluronate, and 2 parts of turmeric extract.

[0032] Preparation method:

[0033] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0034] Comparative Example 1:

[0035] A composition for improving bone and joint health comprises the following components, measured by mass: 2 parts of collagen peptide, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 15.8 parts of turmeric extract.

[0036] Preparation method:

[0037] The product is prepared by mixing collagen peptide, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0038] The difference from Example 1 is that Comparative Example 1 does not contain mangosteen extract, and its amount is added to turmeric extract, and the rest is the same as Example 1.

[0039] Comparative Example 2:

[0040] A composition for improving bone and joint health, comprising the following components by mass: 2 parts of collagen peptide, 15.8 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 0.8 parts of turmeric extract.

[0041] Preparation method:

[0042] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine and sodium hyaluronate.

[0043] The only difference from Example 1 is that Comparative Example 2 does not contain turmeric extract, and its amount is added to the mangosteen extract, and the rest is the same as Example 1.

[0044] Comparative Example 3:

[0045] A composition for improving bone and joint health comprises the following components by mass: 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of N-acetylglucosamine, 0.4 parts of sodium hyaluronate, and 0.8 parts of turmeric extract.

[0046] Preparation method:

[0047] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0048] The only difference from Example 1 is that Comparative Example 3 does not contain cartilage extract, and its amount is added to sodium hyaluronate. Others are the same as Example 1.

[0049] Comparative Example 4:

[0050] A composition for improving bone and joint health comprises the following components by mass: 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.4 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, and 0.8 parts of turmeric extract.

[0051] Preparation method:

[0052] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine and turmeric extract.

[0053] The only difference from Example 1 is that Comparative Example 4 does not contain sodium hyaluronate, and its amount is added to the cartilage extract. The rest is the same as Example 1.

[0054] Comparative Example 5:

[0055] A composition for improving bone and joint health, comprising the following components by mass: 2 parts of collagen peptides, 14.2 parts of mangosteen extracts, 2 parts of non-denatured type II collagen peptides, 0.8 parts of milk mineral salts, 0.8 parts of bone collagen peptides, 1 part of cartilage extracts, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 0.8 parts of turmeric extracts.

[0056] Preparation method:

[0057] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0058] The difference from Example 1 is that the amount of mangosteen extract and cartilage extract and the weight ratio of the two are different. In Example 1, the amount of the two is 15 parts and 0.2 parts, respectively, and the weight ratio of the two is about 75:1; while in Comparative Example 5, the amount of the two is 14.2 parts and 1 part, respectively, and the weight ratio of the two is 14.2:1. Others are the same as in Example 1.

[0059] Comparative Example 6:

[0060] A composition for improving bone and joint health, comprising the following components by mass: 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.4 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.4 parts of sodium hyaluronate, and 0.4 parts of turmeric extract.

[0061] Preparation method:

[0062] The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate and turmeric extract.

[0063] The difference from Example 1 is that the amount and weight ratio of cartilage extract, sodium hyaluronate and turmeric extract are different. In Example 1, 0.2 parts of cartilage extract, 0.2 parts of sodium hyaluronate and 0.8 parts of turmeric extract are used, and the ratio of the three is 2:2:8; while in Comparative Example 6, 0.4 parts of cartilage extract, 0.4 parts of sodium hyaluronate and 0.4 parts of turmeric extract are used, and the ratio of the three is 1:1:1. Other aspects are the same as in Example 1.

[0064] Experimental Example 1: Experiment on the efficacy of drugs on osteoarthritis

[0065] 1. Experimental groups: Wistar male rats were adaptively fed for 7 days and then randomly divided into a normal control group, a model control group, a positive control group, examples 1-3 and comparative examples 1-6, with 10 rats in each group.

[0066] 2. Modeling: 10% papain and 0.03 mol / L L-cysteine ​​were mixed at a ratio of 1:1 and allowed to stand for 30 min before use. On the 1st, 4th and 7th days of the experiment, 0.2 mL of the papain mixed solution was injected into the knee joint cavity of rats in the model control group, the positive control group, the examples 1-3 and the comparative examples 1-6 groups to induce rat osteoarthritis models, and the normal control group was injected with an equal volume of saline.

[0067] 3. Administration: After modeling, administration began on the 8th day of the experiment. The positive control group was gavaged with amino acid glucose hydrochloride (Aotai Ling, produced by Aome Pharmaceutical Company) at a dose of 90 mg / kg, and the Example 1-3 and Comparative Example 1-6 groups were gavaged with samples of Example 1-3 and Comparative Example 1-6 (the compositions of Example 1-3 and Comparative Example 1-6 were dissolved with deionized water before administration), and the dosage was 0.08 g of the composition / kg·d. The normal control group and the model control group were gavaged with the same dose of deionized water. Each rat was gavaged once a day for 4 weeks. The entire experiment, i.e., modeling + administration, lasted for 5 weeks.

[0068] 4. Characterization:

[0069] (1) Observation of the general condition of rats: Observe the rats' mental state, hair, and food intake.

[0070] (2) Changes in the width of both knee joints of rats: The ankle joint widths were measured before modeling, before drug administration, at the second week of drug administration, and at the fourth week of drug administration. The average of the three measurements was taken and the degree of joint swelling was calculated according to the following formula. Degree of joint swelling: Degree of joint swelling (mm) = width of ankle joint after inflammation (after drug administration) (mm) - width of ankle joint before inflammation (mm).

[0071] (3) Two hours after the last intragastric administration, the rats were anesthetized and physiological saline was injected into the knee joint cavities for lavage. The joint lavage fluid was centrifuged at 1500 r / min for 15 min at 4°C, and the supernatant was separated and packaged and frozen at -80°C for later use. The supernatant was taken and the contents of IL-1β, IL-6 and TNF-ɑ in the lavage fluid were determined according to the instructions of the ELISA kit.

[0072] (4) Determination of the content of glycosaminoglycans (GAGs) in rat joint synovial tissue: 24 hours after the last oral administration, the rats were killed, and the synovial tissue of both knee joints was taken, frozen in liquid nitrogen and then transferred to -80°C for future use. An appropriate amount of synovial tissue was taken, added with ice saline, placed in an ice bath, and made into a 2% synovial tissue homogenate using a tissue homogenizer, centrifuged (4°C, 3500r / min, 10min), and the supernatant was taken for future use. The content of glycosaminoglycans (GAGs) in joint synovial tissue was determined by dimethyl methylene blue spectrophotometry according to the instructions.

[0073] All experimental data were analyzed using SPSS 17.0 software. According to the normality and homogeneity of variance of the test data, the data of each group were expressed as ±s, and the t-test was used to compare the significance of the differences between the groups.

[0074] 5. Results:

[0075] (1) Observation results of general condition of rats

[0076] No rats died during the modeling process. After the modeling, the rats in the normal control group moved normally, while the rats in the other groups showed low spirits and slight lameness in the knee joints. After 4 weeks of treatment, the rats in the normal control group had normal knee joint movement, normal diet and drinking water, shiny fur color, and sensitive reaction; the rats in the model control group all had local swelling of the knee joint, less movement, less diet and drinking water, and slow reaction. The swelling of the knee joints, activity, diet, drinking water, and reaction agility of the rats in the other drug-treated groups were improved to varying degrees.

[0077] (2) Changes in the width of the knee joints of rats

[0078] The specific results are shown in Table 1.

[0079] Table 1: Results of the swelling of the rat knee joints

[0080]

[0081]

[0082] Note: Compared with the normal control group, ## P<0.01; compared with the model control group, each drug-treated group *P<0.05, **P<0.01; compared with the Example 1 group, each drug-treated group & indicates P < 0.05, && Indicates P<0.01.

[0083] According to the results in the table, the model control group and the normal control group have significant differences (P < 0.01), indicating that the modeling is successful; compared with the model control group, the drugs of Examples 1-3 and Comparative Examples 1-6 have different degrees of inhibitory effects on joint swelling, among which the positive control group, Example 1-3 group and the model control group have significant differences (P < 0.01), and the difference between Comparative Examples 1-6 group and the model control group is statistically significant (P < 0.05); compared with Example 1 group, there is no statistically significant difference between Example 2, Example 3 and the positive control group and Example 1 group, while there is a statistically significant difference between Comparative Examples 5 and Comparative Examples 6 and Example 1 group (P < 0.05), and there is a significant difference between Comparative Examples 1-4 group and Example 1 group (P < 0.01). It shows that the raw material composition and raw material ratio in the present composition have an effect on the inhibitory effect of joint swelling, and the synergistic combination of the raw material composition and ratio in the composition of the present invention can achieve the best effect.

[0084] (3) Effects on the levels of inflammatory factors IL-1β, IL-6 and TNF-α in rat knee joint lavage fluid

[0085] See Table 2 for specific values.

[0086] Table 2: Effects on the content of inflammatory factors in rat knee joint lavage fluid

[0087]

[0088]

[0089] Note: Compared with the normal control group, **P<0.01; compared with the model control group, each drug group # P<0.05, ## P<0.01; Compared with the group in Example 1, the & indicates P < 0.05, && Indicates P<0.01.

[0090] According to the results in the table, the content of inflammatory factors IL-1β, IL-6 and TNF-α between the model control group and the normal control group was significantly different (P < 0.01). Compared with the model control group, the drugs in the positive control group, Examples 1-3, and Comparative Examples 1-6 all had different degrees of positive regulation on the content of IL-1β, IL-6 and TNF-α; among them, for the content of IL-1β and TNF-α, there were significant differences between the positive control group, Example 1-3 group, Comparative Example 5 group, and Comparative Example 6 group and the model control group (P < 0.01), and the difference between Comparative Example 1-4 group and the model control group was statistically significant (P < 0.05); for the content of IL-6, there were significant differences between the positive control group, Example 1-3 group, Comparative Example 5 group and the model control group (P < 0.01), and the difference between Comparative Example 1-4 group and Comparative Example 6 group and the model control group was statistically significant (P < 0.05). Compared with the Example 1 group, there was no statistically significant difference between the Example 2, Example 3 and the positive control group and the Example 1 group, while there was a statistically significant difference (P < 0.05) or a significant difference (P < 0.01) between the Comparative Examples 1-6 and the Example 1 group. This indicates that the raw material composition and raw material ratio in the composition have an effect on the positive regulation of the content of IL-1β, IL-6 and TNF-α, and the synergistic combination of the raw material composition and ratio in the composition of the present invention can achieve the best effect.

[0091] (4) Effects on the content of glycosaminoglycans (GAGs) in synovial tissue

[0092] See Table 3 for specific values.

[0093] Table 3: Effects on the content of glycosaminoglycans (GAGs) in synovial tissue

[0094]

[0095]

[0096] Note: Compared with the normal control group, **P<0.01; compared with the model control group, each drug group # P<0.05, ## P<0.01; Compared with the group in Example 1, the & indicates P < 0.05, && Indicates P<0.01.

[0097] According to the results in the table, the content of GAGs between the model control group and the normal control group is significantly different (P < 0.01). Compared with the model control group, the drugs of Examples 1-3 and Comparative Examples 1-6 have different degrees of positive regulation on the content of GAGs, and the positive control group, Example 1-3 group, Comparative Example 5 group, Comparative Example 6 group and the model control group have significant differences (P < 0.01), and the difference between Comparative Example 1-4 group and the model control group is statistically significant (P < 0.05); Compared with Example 1 group, there is no statistically significant difference between Example 2, Example 3 and the positive control group and Example 1 group, while the difference between Comparative Example 5-6 group and Example 1 group is statistically significant (P < 0.05), and the difference between Comparative Example 1-4 group and Example 1 group is significant (P < 0.01). It shows that the raw material composition and raw material ratio in the present composition have an effect on the positive regulation of the content of GAGs, and the synergistic combination of the raw material composition and ratio in the composition of the present invention can achieve the best effect.

[0098] In summary, the composition in the embodiment of the present invention has a good inhibitory effect on joint swelling, and has a significant positive regulatory effect on the content of glycosaminoglycans (GAGs) in the synovial tissue of arthritis model rats and the related inflammatory factors IL-1β, IL-6, TNF-α, and the synovial tissue of the joints, and the effect is significantly better than that of the composition of comparative examples 1-6.

[0099] Preparation example:

[0100] Raw material composition: collagen peptide 20g, mangosteen extract 150g, non-denatured type II collagen peptide 20g, milk mineral salt 8g, bone collagen peptide 8g, cartilage extract 2g, N-acetylglucosamine 2g, sodium hyaluronate 2g, turmeric extract 8g, magnesium stearate 4g, microcrystalline cellulose 246g, sorbitol 10g, hydroxypropyl methylcellulose 20g.

[0101] The above raw materials were mixed and pressed into 1000 candy pieces.

[0102] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for improving bone and joint health, comprising the following components by mass: 0.5-5 parts of collagen peptide, 5-30 parts of mangosteen extract, 0.5-3 parts of non-denatured type II collagen peptide, 0.1-2 parts of milk mineral salt, 0.3-3 parts of bone collagen peptide, 0.1-2 parts of cartilage extract, 0.1-2 parts of N-acetylglucosamine, 0.1-2 parts of sodium hyaluronate, and 0.3-3 parts of turmeric extract.

2. The composition according to claim 1, characterized in that The composition comprises the following components by mass: 0.8-3 parts of collagen peptide, 5-20 parts of mangosteen extract, 1-2.5 parts of non-denatured type II collagen peptide, 0.1-1.2 parts of milk mineral salt, 0.5-2 parts of bone collagen peptide, 0.1-1 parts of cartilage extract, 0.1-1 parts of N-acetylglucosamine, 0.1-1 parts of sodium hyaluronate, and 0.5-2 parts of turmeric extract.

3. The composition according to claim 1, characterized in that The composition comprises the following components by mass: 2 parts of collagen peptide, 15 parts of mangosteen extract, 2 parts of non-denatured type II collagen peptide, 0.8 parts of milk mineral salt, 0.8 parts of bone collagen peptide, 0.2 parts of cartilage extract, 0.2 parts of N-acetylglucosamine, 0.2 parts of sodium hyaluronate, and 0.8 parts of turmeric extract.

4. The composition according to claim 1, characterized in that The weight ratio of the mangosteen extract to the cartilage extract is 60-80:

1.

5. The composition according to claim 1, characterized in that The weight ratio of the cartilage extract, sodium hyaluronate and turmeric extract is 1-3:1-3:6-10.

6. The composition according to any one of claims 1 to 5, characterized in that The composition also includes food grade excipients.

7. The composition according to claim 6, characterized in that The auxiliary material is selected from at least one of hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sorbitol, citric acid, xanthan gum, sucralose, maltodextrin, soluble starch and lactose.

8. A method for preparing the composition according to any one of claims 1 to 7, characterized in that: The steps include: The product is prepared by mixing collagen peptide, mangosteen extract, non-denatured type II collagen peptide, milk mineral salt, bone collagen peptide, cartilage extract, N-acetylglucosamine, sodium hyaluronate, turmeric extract and food-grade auxiliary materials.

9. Use of the composition according to any one of claims 1 to 7 or the composition prepared by the preparation method according to claim 8 in preparing a product for preventing or improving osteoarthritis.

10. The use according to claim 9, characterized in that: The product is in the form of liquid, jelly, gel candy, compressed candy or powder.

Images